The Utility of Urine Cytology in Predicting Recurrence following Intravesical Therapy for Non‐Muscle Invasive Bladder Cancer – Expert Commentary

December 10, 2019 Urine cytology plays an essential role in detecting patients who are at high risk for disease recurrence following non-muscle invasive bladder cancer (NMIBC) treatment. A recent study Gupta et al. in the World Journal of Urology evaluated the accuracy of urine cytology in detecting recurrence and progression following therapy for NMIBC. The…

Read the full article here

Source: www.urotoday.com

Categories: Urology

Tags: ExpertCommentary

Tweets with this article

UroToday.com

#ExpertCommentary The utility of urine cytology in predicting recurrence following intravesical therapy for non‐muscle invasive #BladderCancer. @FaltasLab discussion of @MGuptaMD et. al. study. #ReadNow on UroToday > https://t.co/WxjmYuHxLD @EngIPM @WeillCornell @wjurol https://t.co/vX5BbEUfg6

SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC

SES AUA 2025 phase 1 trial of mevrometostat (PF-06821497), mevrometostat with enzalutamide plus ADT, abiraterone.

UroToday.com March 17, 2025

SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Therapy: A Sensitivity Analysis from ARASENS

SES AUA 2025, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), ARASENS trial, Darolutamide, Androgen Deprivation Therapy (ADT), abiraterone, enzalutamide, cabazitaxel.

UroToday.com March 17, 2025

SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial

SES AUA 2025, prostate cancer, Veracyte, Active Surveillance for prostate cancer, SPOP mutations, PTEN mutations, PAM50.

UroToday.com March 17, 2025

SES AUA 2025: Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study

SES AUA 2025 high-risk biochemically recurrent prostate cancer, enzalutamide monotherapy treatment, phase 3 EMBARK study, EMBARK (NCT02319837).

UroToday.com March 17, 2025

SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis

SES AUA 2025, prostate cancer, EMBARK trial, Leuprolide, biochemical recurrence in prostate cancer.

UroToday.com March 17, 2025

Cancer-Related Financial Hardship Among Cancer Survivors: Research from the HINTS-SEER Survey – Apoorv Dhir & Rishi Sekar

Ruchika Talwar interviews Apoorv Dhir and Rishi Sekar about their study on cancer-related financial hardship among cancer survivors. The researchers discuss findings from the HINTS-SEER…

UroToday.com March 17, 2025

SES AUA 2025: American Urological Association Annual Census Identifies 39% of Practicing Urologists Utilize Unhealthy Coping Mechanisms for Burnout and Stress

SES AUA 2025, urologic workforce shortage, coping mechanisms for urologists, stress management for urologists.

UroToday.com March 14, 2025

Related Articles